DK1003552T3 - LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation - Google Patents

LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation

Info

Publication number
DK1003552T3
DK1003552T3 DK97936112T DK97936112T DK1003552T3 DK 1003552 T3 DK1003552 T3 DK 1003552T3 DK 97936112 T DK97936112 T DK 97936112T DK 97936112 T DK97936112 T DK 97936112T DK 1003552 T3 DK1003552 T3 DK 1003552T3
Authority
DK
Denmark
Prior art keywords
proliferation
cd2a antibody
inhibiting
cell activation
cd2a
Prior art date
Application number
DK97936112T
Other languages
English (en)
Inventor
Herve Bazin
Dominique Latinne
Ruth Kaplan
Thomas Kieber-Emmons
Christina E Postema
Mary E White-Scharf
Original Assignee
Biotransplant Inc
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotransplant Inc, Univ Catholique Louvain filed Critical Biotransplant Inc
Application granted granted Critical
Publication of DK1003552T3 publication Critical patent/DK1003552T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DK97936112T 1995-06-07 1997-07-18 LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation DK1003552T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,281 US5817311A (en) 1993-03-05 1995-06-07 Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
PCT/US1997/012645 WO1999003502A1 (en) 1995-06-07 1997-07-18 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION

Publications (1)

Publication Number Publication Date
DK1003552T3 true DK1003552T3 (da) 2008-08-25

Family

ID=26792646

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97936112T DK1003552T3 (da) 1995-06-07 1997-07-18 LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation

Country Status (9)

Country Link
US (1) US5817311A (da)
EP (1) EP1003552B1 (da)
AT (1) ATE395081T1 (da)
AU (1) AU754185B2 (da)
CA (1) CA2295604C (da)
DE (1) DE69738692D1 (da)
DK (1) DK1003552T3 (da)
ES (1) ES2307301T3 (da)
WO (1) WO1999003502A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US7592006B1 (en) * 1993-03-05 2009-09-22 Université Catholique de Louvain Composition comprising the LO-CD2a antibody
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US6849258B1 (en) * 1997-07-18 2005-02-01 Universite Catholique De Louvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
DE69927831T2 (de) * 1998-08-31 2006-07-20 Biogen, Inc., Cambridge Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens
AU2980900A (en) 1999-02-04 2000-08-25 General Hospital Corporation, The Methods for human allografting
US6541611B1 (en) 1999-06-18 2003-04-01 Universite Catholique De Louvain LO-CD2b antibody
GEP20063828B (en) * 2001-02-01 2006-05-10 Biogen Inc Methods for Treating or Preventing Skin Disorders Using CD2-Binding Agents
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2003009740A2 (en) * 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
PT2332989E (pt) 2002-05-22 2015-08-05 Esbatech Alcon Biomed Res Unit Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas
WO2005077018A2 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
KR20070011558A (ko) * 2004-05-04 2007-01-24 제네상스 파머슈티컬스, 아이엔씨. 일배체형 마커 및 치료에 대한 반응을 측정하기 위해 이를이용하는 방법
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
SG190659A1 (en) * 2008-09-02 2013-06-28 Pluristem Ltd Adherent cells from placenta tissue and use thereof in therapy
CN119857155A (zh) 2017-11-29 2025-04-22 海德堡医药研究有限责任公司 用于耗尽cd5+细胞的组合物和方法
MX2021012961A (es) 2019-04-24 2021-11-25 Heidelberg Pharma Res Gmbh Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
KR20220051164A (ko) 2019-07-05 2022-04-26 아이오엠엑스 테라퓨틱스 아게 Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도
WO2022008027A1 (en) 2020-07-06 2022-01-13 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof
AU2023356326A1 (en) 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1991001752A1 (en) * 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
EP0687300B1 (en) * 1993-03-05 2001-09-12 Universite Catholique De Louvain LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T-CELL ACTIVATION AND PROLIFERATION

Also Published As

Publication number Publication date
AU3886297A (en) 1999-02-10
CA2295604A1 (en) 1999-01-28
US5817311A (en) 1998-10-06
DE69738692D1 (de) 2008-06-26
EP1003552A4 (en) 2002-10-02
WO1999003502A1 (en) 1999-01-28
ES2307301T3 (es) 2008-11-16
CA2295604C (en) 2008-09-30
ATE395081T1 (de) 2008-05-15
EP1003552B1 (en) 2008-05-14
HK1025738A1 (en) 2000-11-24
AU754185B2 (en) 2002-11-07
EP1003552A1 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
ATE132197T1 (de) Monoklonale antikörper
DE69726426D1 (de) Unterdrückung von immunantwort durch hemmung von cathepsin s
DK0687300T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
DK0610335T3 (da) Fremgangsmåder til udformning af rekombitope peptider
NO973875D0 (no) Fremgangsmåte for simulering av en immunrespons
NO922621D0 (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
WO2000078814A3 (en) LO-CD2b ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION
PT959899E (pt) Anticorpo lo-cd2a e suas utilizações para inibir a activação e proliferação de células t
DK1021196T3 (da) Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
DK0837672T3 (da) Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme
DE69839943D1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
ATE245661T1 (de) Natürliche menschliche igm antikörper
ATE156711T1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
Ishizaka T cell factors involved in the regulation of the IgE antibody response